Investment Thesis
Cytosorbents exhibits a financially distressed profile with unsustainable losses (-$5.1M net income, -$1.2M operating cash flow) despite a strong 69.2% gross margin, indicating the core product has merit but operations are severely inefficient. Dangerously high leverage (7.73x Debt/Equity) combined with tight liquidity (1.09x current ratio, 0.81x quick ratio) and minimal equity cushion ($2.2M) create substantial refinancing and solvency risk, far outweighing modest revenue growth of 4.1%.
Strengths
- Strong gross margin of 69.2% demonstrates viable product and pricing power
- Revenue growing 4.1% YoY with positive market traction in medical devices
- Net losses improving 65.8% YoY from -$0.22 to -$0.08 per share, showing trend toward breakeven
Risks
- Severe operating losses (-$3.0M) and negative free cash flow (-$1.2M) with no clear path to profitability
- Dangerously high leverage at 7.73x Debt/Equity with $17.0M long-term debt against $2.2M equity base
- Tight liquidity and solvency risk: current ratio 1.09x, quick ratio 0.81x, and minimal equity buffer for adverse events
- Operating expenses far exceed gross profit, indicating severe scaling inefficiency relative to revenue base
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Operating expense reduction and gross profit leverage into profitability
- Debt refinancing risk and covenant compliance with current leverage levels
Financial Metrics
Revenue
8.9M
Net Income
-5.1M
EPS (Diluted)
$-0.08
Free Cash Flow
-1.2M
Total Assets
40.6M
Cash
4.8M
Profitability Ratios
Gross Margin
69.2%
Operating Margin
-34.3%
Net Margin
-57.9%
ROE
-233.8%
ROA
-12.6%
FCF Margin
-13.2%
Balance Sheet & Liquidity
Current Ratio
1.09x
Quick Ratio
0.81x
Debt/Equity
7.73x
Debt/Assets
94.6%
Interest Coverage
N/A
Long-term Debt
17.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:04:06.665392 |
Data as of: 2026-03-31 |
Powered by Claude AI